Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model

Vaccine

Volumn 14, Issue 9, 1996, Pages 841-844

  Devi, Sarvamangala J N ^a,b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Conjugate vaccine; Cryptococcus neoformans; Humoral protection

Indexed keywords

TETANUS TOXOID; VACCINE;

ANTIBODY RESPONSE; ARTICLE; CRYPTOCOCCUS NEOFORMANS; HUMAN; IMMUNIZATION; MENINGOENCEPHALITIS; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

EID: 0030174340     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00256-Z     Document Type: Article

References (29)

1. 1 Zuger, A., Louie, E., Holzman, R.S., Simberkoff, M.S. and Rahal, J.J. Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann. Intern. Med. 1986, 104, 234-240
2. 2 Drouhet, E., Dupont, B., Bossche, H.V., Mackenzie, D.W.R., Cauwenbergh, G., Cutseum, J.V., Drouhet, E. and Dupont, B. Mycoses in AIDS Patients. 1990, 27-53. Plenum Press, New York
3. 3 Pinner, R.W., Hutwagner, L. and Collins, S. 33rd Ann. Intersci. Conf. Antimicrob. Agents and Chemother., Chicago, 1993, abstr., p. 167
4. 4 Shimizu, R.Y., Howard, D.H. and Clancy, M.N. The variety of Cryptococcus neoformans in patients with AIDS. J. Infect. Dis. 1986, 154, 1042
5. 5 Graybill, J.R. and Alford, R.H. Cell-mediated immunity in cryptococcosis. Cell. Immun. 1974, 14, 12-21
6. 6 Kozel, T.R. Jr and Cazin, J. Non-encapsulated variant of Cryptococcus neoformans. Infect. Immun. 1971, 3, 287-294
7. 7 Fromtling, R.A., Shadomy, H.J. and Jacobson, E.S. Decreased virulence in stable, acapsular mutants of Cryptococcus neoformans. Mycopathologia 1982, 79, 23-29
8. 8 Eng, R.H.K., Bishburg, E., Smith, S.M. and Kapila, R. Cryptococcal infections in patients with acquired immune deficiency syndrome. Am. J. Med. 1986, 81, 19-23
9. 9 Henderson, D.K., Bennett, J.E. and Huber, M.A. Long-lasting specific immunologic unresponsiveness associated with cryptococcal meningitis. J. Clin. Invest. 1982, 69, 1185-1190
10. 10 Murphy, J.W. and Cozad, G.C. Immunological unresponsiveness induced by cryptococcal polysaccharide assayed by the hemolytic plaque technique, Infect. Immun. 1972, 5, 896-901
11. 11 Diamond, R.D. and Bennett, J.E. Prognostic factors in cryptococcal meningitis. A study of 111 cases. Ann. Intern. Med. 1974, 80, 176-181
12. 12 Dromer, F., Aucouturier, P., Clauvel, J-P., Saimot, G. and Yeni, P. Cryptococcus neoformans antibody levels in patients with AIDS. Scand. J. Infect. Dis. 1988, 20, 283-285
13. 13 Scott, E.N., Muchmore, H.G. and Felton, F.G. Enzyme-linked immunosorbent assays in murine cryptococcosis. Sabouraudia 1981, 19, 257-265
14. 14 Graybill, J.R., Hague, M. and Drutz, D.J. Passive immunization in murine cryptococcosis. Sabouraudia 1981, 19, 237-244
15. 15 Dromer, F., Charreire, J., Contrepois, A., Carbon, C. and Yeni, P. Protection of mice against experimental cryptococcus infection by anti-C. neoformans monoclonal antibody. Infect. Immun. 1987, 55, 749-752
16. 16 Mukherjee, J., Scharff, M.D. and Casadevall, A. Protective monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 1992, 60, 4534-4541
17. 17 Sanford, J.E., Lupan, D.M., Schlageter, A.M. and Kozel, T.R. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with capsular polysaccharide. Infect. Immun. 1990, 58, 1919-1923
18. 18 Dromer, F. and Charreire, J. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J. Infect. Dis. 1991, 163, 1114-1120
19. 19 Mukherjee, J., Zuckier, L.S., Scharff, M.D. and Casadevall, A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob. Agents Chemother. 1984, 38, 580-587
20. 20 Kozel, T.R. and Cazin, J. Jr Induction of humoral response by soluble polysaccharide to Cryptococcus neoformans. Mycopathol. Mycol. Appl. 1974, 54, 21-23
21. 21 Dromer, F., Yeni, P. and Charreire, J. Genetic control of the humoral response to cryptococcal capsular polysaccharide in mice. Immunogenetics 1988, 28, 417-424
22. 22 Devi, S.J.N., Schneerson, R., Egan, W. et al. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization and immunogenicity. Infect. Immun. 1991, 59, 3700-3707
23. 23 Casadevall, A., Mukherjee, J., Devi, S.J.N., Schneerson, R., Robbins, J.B. and Scharff, M.D. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 1992, 65, 1086-1093
24. 24 Bennett, J.E. and Bailey, J.W. Control for rheumatoid factor in the latex test for cryptococcosis. Am. J. Clin. Pathol. 1971, 56, 360-365
25. 25 Devi, S.J.N., Robbins, J.B. and Schneerson, R. Antibodies to poly [(2-8)-α-N-acetylneuraminic acid] and poly [(2-9)-α-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc. Natl Acad. Sci. USA 1991, 88, 7175-7179
26. 26 Chu, C.-Y, Schneerson, R.S., Robbins, J.B. and Rastogi, S. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect. Immun. 1983, 40, 245-256
27. 27 Kozel, T.R. and Follette, J.L. Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody. Infect. Immun. 1981, 31, 978-984
28. 28 Diamond, R.D. Antibody-dependent killing of Cryptococcus neoformans by human peripheral blood mononuclear cells. Nature 1974, 247, 148-150
29. 29 Nabavi, N. and Murphy, J.W. Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans. Infect. Immun. 1986, 51, 556-562